Scilex Holding Co
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
SCLX$1.61-7.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities | ||
| Net loss including noncontrolling interest | $(160,636) | $(70,128) |
| Adjustments to reconcile net loss to net cash used for operating activities: | ||
| Depreciation and amortization | 5,708 | 2,013 |
| Amortization of debt issuance costs and debt discount | 2,015 | — |
| Non-cash operating lease cost | 771 | 357 |
| Non-cash expense from repurchase of preferred shares of Vivasor | 1,147 | — |
| Stock-based compensation | 7,224 | 6,593 |
| Vivasor - stock-based compensation warrants | 1,164 | — |
| Loss on disposition of property and equipment | 26 | — |
| (Gain) loss on derivative liability | (19,065) | 1,966 |
| Loss on compound derivative of Scilex-St. James Loans | 28,759 | — |
| Financing costs and allocated expense for financial instruments at fair value | — | 4,057 |
| Change in fair value of debt and liability instruments | 3,029 | 14,480 |
| Change in fair value of Aardvark contingent consideration | 1,535 | — |
| In-process research and development expense | — | 4,916 |
| Unrealized loss on digital assets, net | 27,322 | — |
| Unrealized loss on equity method investments carried at fair value, net | 82,447 | — |
| Realized gain on equity method investments carried at fair value, net | (37,084) | — |
| Realized loss on securities | 3,066 | — |
| Allowances for expected credit losses | 873 | — |
| Non-cash revenue | (1,131) | — |
| Gain from property in kind dividend | (525) | — |
| Other | 733 | 77 |
| Changes in operating assets and liabilities: | ||
| Accounts receivables, net | 8,732 | 9,675 |
| Inventory | 617 | (88) |
| Prepaid expenses and other | (1,000) | 1,466 |
| Other long-term assets | (994) | — |
| Accounts payable | 19,591 | 6,856 |
| Accrued payroll | 838 | 128 |
| Accrued expenses | (4,357) | 599 |
| Accrued rebates and fees | 24,301 | 30,423 |
| Operating lease liability | 508 | (343) |
| Other current liabilities | (3,657) | — |
| Other long-term liabilities | 199 | 10 |
| Net cash (used for) proceeds from operating activities | (7,844) | 13,057 |
| Investing activities | ||
| Cash paid for in-process research and development, net | — | (200) |
| Purchase of patent | (2,900) | — |
| Acquisition consideration paid in cash for Romeg intangible asset acquisition | (300) | (300) |
| Payments made for PA OPS investment | (500) | — |
| Purchases of Bitcoin | (18,700) | — |
| Purchases of Digital Assets | (49) | — |
| Repayments on promissory note | (1,410) | — |
| Purchases of property and equipment | (593) | — |
| Proceeds from sale of property and equipment | 15 | — |
| Purchase of preferred shares of Vivasor | (300) | — |
| Issuance of convertible note receivable for QScan | (20,000) | — |
| Sale of Datavault shares for cash, net | 47,333 | — |
| Payment made for Datavault licenses | (6,250) | — |
| Sale of Marketable Securities | 2,945 | — |
| Purchase of convertible promissory note from Denali | — | (48) |
| Net cash used for investing activities | (709) | (548) |
| Financing activities | ||
| Installment payment of Tranche B Note | (6,319) | (8,874) |
| Payments on purchased revenue liability | (1,192) | (1,156) |
| Payments of Vivasor debt | (2,475) | — |
| Acquisition of controlling interest in Vivasor | 1,500 | — |
| Repurchase of preferred shares of Vivasor | (2,376) | — |
| Proceeds from issuance of St James Loan, net of issuance costs | 15,502 | — |
| Proceeds from stock options exercised and ESPP | 21 | 17 |
| Transaction costs paid in connection with share repurchase | — | (696) |
| Excise tax paid in connection with share repurchase | — | (709) |
| Payments of deferred transaction costs related to Semnur Business Combination | — | (263) |
| Payments in lieu of fractional shares for Reverse Stock Split | — | (1) |
| Net cash provided by (used for) financing activities | 4,661 | (11,682) |
| Effect of exchange rate changes on cash | (497) | — |
| Net change in cash and cash equivalents | (4,389) | 827 |
| Cash and cash equivalents at beginning of period | 4,955 | 3,272 |
| Cash and cash equivalents at end of period | $566 | $4,099 |
| Non-cash investing and financing activities | ||
| Settlement of St. James Loans for Datavault shares | 66,296 | — |
| Purchase of preferred shares of Vivasor included in accrued expenses | 750 | — |
| Repurchase of common stock shares of Vivasor included in accrued expenses | 748 | — |
| Reclassification of prepayment related to QScan investment | 2,500 | |
| Stock dividend declared in 2024, and canceled in February 2026 | 1 | — |
| Semnur dividend of Semnur Pharmaceuticals Inc. shares | 4,230 | — |
| Interest expense accrued and added to principal balance of promissory notes | 70 | — |
| Deferred transaction costs related to Semnur Business Combination included in accrued expenses and account payable | — | 2,209 |
| Additions to intangible assets included in accrued expenses | — | 1,000 |
| Acquisition of interest in joint venture in accrued expenses | — | 1,100 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.